Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pentachlorophenol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.91 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 8/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.91 |
| ▸ | TSHR | P16473 | 7/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.91 |
| ▸ | MAPT | P10636 | 3/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentachlorophenol SCHEMBL27483459 | 0.96 | HPGD (0.83) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL15486969 | 0.96 | HPGD (0.83) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL21065116 | 0.96 | HPGD (0.83) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Perchlorobenzene SCHEMBL28269084 | 0.95 | HSD17B10 (1.00) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL5315995 | 0.95 | HSD17B10 (1.00) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL23121452 | 0.95 | HSD17B10 (1.00) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL1330735 | 0.95 | HSD17B10 (1.00) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL1492 | 0.95 | HSD17B10 (1.00) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL10581939 | 0.92 | TSHR (0.77) | HPGDHSD17B10TSHRALDH1A1MEN1 | |
| Pentachlorophenol SCHEMBL21647360 | 0.91 | HSD17B10 (0.91) | HPGDHSD17B10TSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58045499-A | — | — | None | — | — | JP | disclosed |
| JP-10218619-A | — | — | None | — | — | JP | disclosed |
| JP-4193977-A | — | — | None | — | — | JP | disclosed |
| US-20260097043-A1 | NOVEL FORMULATIONS AND VEHICLES | WISTA LABORATORIES LTD. (SG) | 2026-04-09 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | WISTA LABORATORIES LTD (SG) | 2026-02-19 | — | — | US | disclosed |
| US-20260049001-A1 | METHOD FOR PRODUCING ULTRA HIGH PURE MANGANESE SULFATE MONOHYDRATE | BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) | 2026-02-19 | — | — | US | disclosed |
| EP-4385512-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-4364801-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-0263029-A1 | Insulating product made in situ, fibres or particles included in its composition, and production process | ISOVER SAINT-GOBAIN (FR) | 1988-04-06 | — | — | EP | disclosed |
| US-4713115-A | FILLING HOLES WITH CLINKER SLURRY AND SINTERING | SUMITOMO CEMENT CO., LTD. (JP) | 1987-12-15 | — | — | US | disclosed |
| US-4559186-A | FORMING A QUEOUS GEL, MOLDING | CIBA GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| US-4436805-A | IMPROVED DENSITY, CONTRAST, SHARPNESS | MITSUBISHI PAPER MILLS, LTD. (JP) | 1984-03-13 | — | — | US | disclosed |
| JP-S5845499-A | HEAT ACCUMULATING MATERIAL | HITACHI LTD | 1983-03-16 | — | — | JP | disclosed |
| EP-0001368-B1 | PROCESS FOR GRANULATING SODIUM METASILICATE AND RESULTING PRODUCTS | RHONE-POULENC CHIMIE DE BASE (FR) | 1981-12-09 | — | — | EP | disclosed |
| US-4255593-A | IN SOLVENT, CLOSED SYSTEM | CHAPMAN CHEMICAL COMPANY (US) | 1981-03-10 | — | — | US | disclosed |
| US-4066787-A | Stabilized prostaglandin composition and the process for the preparation thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1978-01-03 | — | — | US | disclosed |
| US-3993488-A | Photograhic film assembly comprising light intercepting elements located behind pressure plate | FUJI PHOTO FILM CO., LTD. (JA) | 1976-11-23 | — | — | US | disclosed |
| US-3965169-A | COMPLEXING, DETERGENT BUILDER, DESICCANT | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048066-A1 | TREATMENT OF NEURODEGENERATIVE DISORDERS UTILISING METHYLTHIONINIUM (MT)-CONTAINING COMPOUNDS | MAPT, PARK7, TARDBP | MEN1 614/4885THRB 3170/4885HPGD 4355/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | MEN1 460/4885THRB 256/4885HPGD 2650/4885 |
| US-20260049001-A1 | METHOD FOR PRODUCING ULTRA HIGH PURE MANGANESE SULFATE MONOHYDRATE | AS3MT, SAMM50, ITPR3 | MEN1 470/4885THRB 1737/4885HPGD 4731/4885 |
| US-20260097043-A1 | NOVEL FORMULATIONS AND VEHICLES | TPMT, PARK7, HTT | MEN1 2542/4885THRB 1978/4885HPGD 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.